Stockscreener 앱 받기
1.24
2.48%
0.03
시간 외 거래:
1.21
-0.03
-2.42%
전일 마감가:
$1.21
열려 있는:
$1.22
하루 거래량:
694.11K
Relative Volume:
1.38
시가총액:
$76.78M
수익:
$248.00K
순이익/손실:
$-113.22M
주가수익비율:
-0.6733
EPS:
-1.8416
순현금흐름:
$-98.81M
1주 성능:
+7.83%
1개월 성능:
+0.00%
6개월 성능:
-21.52%
1년 성능:
-3.88%
1일 변동 폭
$1.21
$1.26
1주일 범위
$1.1538
$1.26
52주 변동 폭
$1.09
$1.95
Pliant Therapeutics Inc Stock (PLRX) Company Profile
명칭
Pliant Therapeutics Inc
전화
650-481-6770
주소
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.24 | 74.92M | 248.00K | -113.22M | -98.81M | -1.8416 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-03-04 | 재개 | Cantor Fitzgerald | Neutral |
| 2025-03-04 | 다운그레이드 | Needham | Buy → Hold |
| 2025-03-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-10 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-02-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-02-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-05-18 | 개시 | Canaccord Genuity | Buy |
| 2023-04-13 | 개시 | Robert W. Baird | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-07 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Outperform |
| 2022-05-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-11-24 | 개시 | RBC Capital Mkts | Outperform |
| 2021-11-03 | 개시 | H.C. Wainwright | Buy |
| 2021-04-20 | 개시 | BTIG Research | Buy |
| 2021-04-05 | 개시 | Citigroup | Buy |
| 2020-06-29 | 개시 | Citigroup | Buy |
| 2020-06-29 | 개시 | Cowen | Outperform |
| 2020-06-29 | 개시 | Needham | Buy |
| 2020-06-29 | 개시 | Piper Sandler | Overweight |
모두보기
Pliant Therapeutics Inc 주식(PLRX)의 최신 뉴스
Pliant Therapeutics to present Phase 1b trial data of PLN-101095 at ASCO 2026. - Pluang
Pliant Therapeutics (PLRX) Bounces 2.5% as Biotech Tests Key ResistanceStock Idea Network - newser.com
Global oncology researchers to review FORTIFY data as Pliant Therapeutics joins ASCO meeting - Traders Union
Pliant Therapeutics (PLRX) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.32Crowd Entry Signals - newser.com
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical ... - Caledonian Record
Pliant Therapeutics Announces Upcoming Presentation at the - GlobeNewswire
Phase 1 cancer trial pairs oral integrin inhibitor with pembrolizumab - Stock Titan
Pliant Therapeutics (PLRX) Stock: Consolidating at $1.20 — Next Move Ahead 2026-05-21Equity Put Call - Newser
Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Australian biotech advancing pulmonary program adds Pliant CEO as chair - Stock Titan
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board - Quantisnow
TradingKey - TradingKey
Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX) - The Globe and Mail
Number of shareholders of Pliant Therapeutics, Inc. – MUN:9PT - TradingView
CCORF Downgrades Pliant Therapeutics(PLRX.US) to Hold Rating, Maintains Target Price $3 - Moomoo
A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $2 to $3 - Moomoo
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - markets.businessinsider.com
Pliant Therapeutics (PLRX) Advances Clinical Trials and Pipeline Development - GuruFocus
Pliant Therapeutics Q1 net loss narrows on lower expenses - TradingView
Pliant Therapeutics (NASDAQ: PLRX) cuts Q1 2026 net loss to $20M - Stock Titan
Pliant Therapeutics (PLRX) narrows Q1 2026 loss as PLN-101095 shows early responses - Stock Titan
Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Lowered by Wall Street Zen - MarketBeat
PLRX (Pliant Therapeutics) quarterly loss narrower than feared; shares tick up as pipeline hopes support sentiment.Margin Improvement - newser.com
The industry tailwinds powering Pliant Therapeutics (PLRX) growth (Smart Money Flows) 2026-05-08Social Buy Zones - Newser
Pliant CEO, CFO to join RBC healthcare fireside chat on May 19 - Stock Titan
PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Pliant Therapeutics Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Pliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street Zen - MarketBeat
Pliant Therapeutics (PLRX) Initiates Key Clinical Trial for Canc - GuruFocus
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors - Investing News Network
Pliant Therapeutics begins trial of cancer drug combination By Investing.com - Investing.com South Africa
Pliant Therapeutics begins trial of cancer drug combination - Investing.com
Pliant Therapeutics Announces First Patient Dosed in - GlobeNewswire
Pliant Therapeutics (PLRX) price target decreased by 17.95% to 2.72 - MSN
Pliant Therapeutics Inc (FRA:9PT) Stock Price & 30 Year Financial Data - GuruFocus
Wall Street Zen Downgrades Pliant Therapeutics (NASDAQ:PLRX) to Sell - MarketBeat
Pliant Therapeutics (NASDAQ: PLRX) outlines 2026 virtual meeting, board changes and pay vote - Stock Titan
[ARS] PLIANT THERAPEUTICS, INC. SEC Filing - Stock Titan
Pliant Therapeutics, Inc. (PLRX) Presents at AACR Annual Meeting 2026Slideshow (NASDAQ:PLRX) 2026-04-21 - Seeking Alpha
Primary Sclerosing Cholangitis (PSC) Market is expected to Hit - openPR.com
Pliant Therapeutics (PLRX) Reports Promising Updates on PLN-101095 Trials - GuruFocus
Pliant Therapeutics (PLRX) Reports Promising Updates on PLN-1010 - GuruFocus
Pliant Therapeutics (PLRX) Stock: Movement Analysis (Breakout Watch) 2026-04-18Elite Trading Signals - Cổng thông tin điện tử tỉnh Lào Cai
Pliant presents updated cancer trial data at AACR meeting By Investing.com - Investing.com South Africa
Pliant Therapeutics presents updated Phase 1 data for PLN-101095 in ICI-refractory tumors - Traders Union
Pliant presents updated cancer trial data at AACR meeting - Investing.com
Pliant Therapeutics : Final AACR 2026 PLN10195 Yap - marketscreener.com
Pliant Therapeutics Says Pln-101095 Generally Well Tolerated; Most Common Trae Was Rash, One Grade 3 Trae Observed - TradingView
Pliant Therapeutics Announces Presentation of Updated Data - GlobeNewswire
Pliant Therapeutics Inc (PLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):